z-logo
Premium
Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C[Note 1. Abbreviations: HAV, hepatitis A virus; HCV, hepatitis C virus. ...]
Author(s) -
Vento S.
Publication year - 2000
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.2000.00019.x
Subject(s) - fulminant hepatitis , medicine , fulminant , superinfection , immunology , coinfection , hepatitis c virus , hepatitis , hepatitis a , chronic liver disease , cirrhosis , fulminant hepatic failure , liver disease , virology , virus , liver transplantation , transplantation
There have been conflicting reports of the clinical outcome of acute hepatitis A virus (HAV) infection in patients with chronic hepatitis C virus (HCV) infection. A prospective study evaluated 432 patients with chronic hepatitis C (183 with cirrhosis) over a 7‐year period. Of the 17 patients with concurrent HAV infection, seven developed fulminant hepatitis and six died. None of these patients had cirrhosis; however, the HLA phenotype (A1; B8:DR3) appeared to be a significant factor in the development of fulminant hepatitis. Patients with this phenotype had high titres of antinuclear antibodies, antismooth muscle antibodies and antiasialoglycoprotein‐receptor antibodies, possibly reflecting the induction of autoimmune hepatitis in this group. The high frequency of fulminant hepatitis in patients with HAV/HCV coinfection contrasts with other surveys, although a large Centers for Disease Control and Prevention (CDC) survey demonstrated that HAV infection in patients with pre‐existing chronic liver disease (CLD) is associated with increased mortality. It is likely that CLD has some importance as an underlying factor in the development of fulminant hepatitis following HAV infection. Further prospective studies are needed to clarify this issue.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here